HCW Biologics to Showcase Important Updates
HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors
MIRAMAR, Fla., -- HCW Biologics Inc., a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and age-related diseases, announced today that its scientists have successfully developed second-generation, multi-specific T-cell engagers against solid tumors, particularly for pancreatic cancer, using its novel proprietary TRBC product discovery and development platform technology.
The TRBC technology enabled the Company to construct T-cell engagers that not only target cancer antigens and CD3 activation of effector T cells, but also simultaneously reduce the immunosuppression in tumor microenvironment. Such immunosuppression plays a pivotal role in reducing effector T-cell infiltration and anti-tumor efficacy in solid tumors. The Company’s two lead T-cell engagers target tissue factor and mesothelin, which are proven solid tumor antigens.
These product candidates exhibit potent and antigen-specific anti-pancreatic cancer activities both in vitro and in humanized mouse models at dose levels that are well tolerated. Dr. Hing C. Wong, Founder and CEO of the Company, will present the details of these IND-enabling studies as an invited speaker for the Phoenix Best Science Series, hosted by HonorHealth Research Institute, located at HonorHealth Scottsdale Shea Medical Center in Scottsdale, Arizona, on June 27, 2025.
Dr. Wong stated, “T-cell engagers revolutionized the immunotherapeutic approach against cancer. Currently, T-cell engagers have approval from the U.S. Food and Drug Administration to be used in the treatment of a small number of indications, including various hematological and solid tumors. Now, we are very excited to report that our proprietary TRBC product discovery platform can be used to create potentially highly effective T-cell engagers against difficult-to-treat solid tumors by using exceptional targets while managing immunosuppression. In our preclinical studies, after treatment with our TRBC-based T-cell engagers, there was 100% survival among tumor-bearing mice in the test group, whereas none of the untreated mice survived. We believe our approach could expand the number of indications that can be treated with T-cell engagers, including enhancing health span for patients suffering with solid tumors, especially diseases such as pancreatic cancer and glioblastoma.”
Dr. Wong continued, “I am very honored to be invited to present at the Phoenix Best Science Series, organized by HonorHealth Research Institute, and join a renowned group of medical and research experts who are at the forefront of the treatment of pancreatic cancer. I look forward to sharing, with this esteemed group, our findings and the basis for our confidence in the potential of our innovative TRBC technology and its derived T-cell engagers against pancreatic cancer and other solid tumors. We believe we are at the cutting edge for expanding the indications that may be treated with T-cell engagers.”
About HCW Biologics
HCW Biologics Inc. is a clinical-stage biopharmaceutical company developing proprietary immunotherapies to treat diseases promoted by chronic inflammation, especially age-related and senescence-associated diseases. The Company’s immunotherapeutics represent a new class of drug that it believes have the potential to fundamentally change the treatment of cancer and many other diseases and conditions that are promoted by chronic inflammation — and in doing so, improve patients’ quality of life and potentially extend longevity. The Company’s lead product candidate, HCW9302, was developed using the Company’s legacy TOBI™ (Tissue factOr-Based fusIon) platform. The Company has created another drug discovery technology, the TRBC platform, which is not based on Tissue Factor. The TRBC platform has the capability to construct immunotherapeutics that not only activate and target immune responses but are also equipped with receptors that specifically target cancerous or infected cells. This platform is a versatile scaffold that enables the creation of multiple classes of immunotherapeutic compounds.
